SCHEMBL10075729

SCHEMBL10075729

CC(=O)O/N=C(\C)C(=O)c1ccc(Sc2ccc(C(=O)O)cc2C(=O)O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.38
ALDH1A1 P00352 6/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 4/20 0.37
KMT2A Q03164 2/20 0.37
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
TSHR P16473 2/20 0.35
GAA P10253 1/20 0.35
RAB9A P51151 1/20 0.35
APEX1 P27695 2/20 0.34
HPGD P15428 5/20 0.33
MAPT P10636 4/20 0.33
LMNA P02545 3/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075765 0.87 TSHR (0.38) KDM4EALDH1A1L3MBTL1KMT2ARXRA
SCHEMBL10075708 0.84 HPGD (0.44) KDM4EALDH1A1L3MBTL1KMT2ARXRA
SCHEMBL10075829 0.83 TTR (0.38) KDM4EALDH1A1L3MBTL1KMT2ARXRA
SCHEMBL10075834 0.82 KDM4E (0.38) KDM4EALDH1A1L3MBTL1KMT2ARXRA
SCHEMBL20935148 0.81 L3MBTL1 (0.50) KDM4EALDH1A1L3MBTL1KMT2ARXRA
SCHEMBL10075723 0.79 L3MBTL1 (0.35) KDM4EALDH1A1TDP1L3MBTL1KMT2A
SCHEMBL16019156 0.79 HPGD (0.56) ALDH1A1L3MBTL1KMT2ARAB9AHPGD
SCHEMBL19795435 0.79 HPGD (0.56) ALDH1A1L3MBTL1KMT2ARAB9AHPGD
SCHEMBL24489413 0.76 L3MBTL1 (0.44) KDM4EALDH1A1L3MBTL1KMT2AHPGD
SCHEMBL19795439 0.76 L3MBTL1 (0.57) KDM4EALDH1A1TDP1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586827-B1 CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2017-12-27 EP disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
EP-2586827-A1 CURABLE RESIN COMPOSITION Adeka Corporation (JP) 2013-05-01 EP disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
EP-2327689-B1 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORP (JP) 2012-02-29 EP disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
EP-2327689-A1 Oxime ester compound and photopolymerization initiator containing the same Adeka Corporation (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, OR10J3, CDK11B KDM4E 1122/4885ALDH1A1 2329/4885TDP1 3287/4885
US-20120115972-A1 CURING RESIN COMPOSITION LTA, LOXL1, PLOD2 KDM4E 15/4885ALDH1A1 203/4885TDP1 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.